Alterity Therapeutics Phase 2 Data Monitoring Committee Reco

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 -- Alterity Therapeutics , a...

Related Keywords

Melbourne , Victoria , Australia , United States , San Francisco , California , Hannah Howlett , Remy Bernarda , David Stamler , Drug Administration , Data Monitoring Committee , Securities Exchange , System Atrophy National Institute Of Neurological Disorders , Nasdaq , Alterity Therapeutics , European Commission , Line Data Expected , Chief Executive Officer , Multiple System Atrophy , System Atrophy , National Institute , Neurological Disorders , Media Contacts , Securities Act , Securities Exchange Act , Annual Report , Markets ,